Today is May 23, 2024. All times in Eastern Daylight Time.
TME PHARMA ANNONCE QUE 33% DES PATIENTS AYANT REÇU LE NOX-A12 EN COMBINAISON AVEC LE BEVACIZUMAB ET LA RADIOTHÉRAPIE ONT ATTEINT DEUX ANS DE SURVIE DANS L'ESSAI DE PHASE 1/2 GLORIA DANS LE CANCER DU CERVEAU
04/23/2024 - 02:00 AM
BUSINESS WIRE
Markteinführung des bahnbrechenden Screening-Tests von Antech in Europa zur Früherkennung von Krebs bei Hunden
04/23/2024 - 02:00 AM
BUSINESS WIRE
Lancio in Europa del rivoluzionario strumento di screening tumorale di Antech, a supporto della diagnosi precoce delle neoplasie del cane
04/23/2024 - 02:00 AM
BUSINESS WIRE
Legrand poursuit ses investissements dans les segments porteurs
04/23/2024 - 02:00 AM
BUSINESS WIRE
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
04/23/2024 - 02:00 AM
BUSINESS WIRE
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
04/23/2024 - 02:00 AM
BUSINESS WIRE
Legrand pursues its investments in buoyant segments
04/23/2024 - 02:00 AM
BUSINESS WIRE
Lanzamiento en Europa de la innovadora herramienta de cribado del cáncer de Antech, para la detección precoz del cáncer canino
04/23/2024 - 02:00 AM
BUSINESS WIRE
Next 15 Group plc UK Regulatory Announcement: Transaction in Own Shares
04/23/2024 - 02:00 AM
BUSINESS WIRE
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
04/23/2024 - 02:00 AM
BUSINESS WIRE
1
...
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
« Previous
Next »